Overview

Trial of Immunotherapy With Avelumab and Pepinemab As Second Line After Folfirinox For Patients With Metastatic Pancreatic Adenocarcinoma

Status:
Not yet recruiting

Trial end date:
2028-12-31

Target enrollment:

Participant gender:

Summary

This trial will assess the safety and tolerability of Pepinemab in combination with Avelumab in patients with metastatic pancreatic adenocarcinoma that has progressed after first line chemotherapy. Phase 2 will assess the efficacy of this combination therapy.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Rochester

Treatments:

Avelumab